Российский кардиологический журнал (Jun 2024)

Role of retinol binding protein 4, visfatin, omentin-1 and vaspin in gout patients with various obesity phenotypes

  • N. N. Pavlova,
  • E. V. Volgina,
  • T. A. Medvedeva,
  • N. Yu. Mishko

DOI
https://doi.org/10.15829/1560-4071-2024-5871
Journal volume & issue
Vol. 29, no. 5

Abstract

Read online

Aim. To study the serum level of retinol-binding protein 4 (RBP4), visfatin, omentin-1 and vaspin in gout patients with different obesity phenotypes, as well as to assess the dynamics of studied parameters against the background of weight loss using an analog of glucagon-like peptide-1 (GLP-1) liraglutide.Material and methods. A total of 117 men with gout during the attack-free interval were examined. The patients were divided into 2 following groups: the 1st group consisted of 43 patients with a metabolically healthy obesity (MHO) and body mass index (BMI) ≥30 kg/m2; the second group consisted of 74 people with an metabolically unhealthy obesity (MUO) (carbohydrate metabolism disorders, hypertension (HTN) and BMI ≥30 kg/m2). The control group was represented by 38 respondents with a class 1 MHO. The blood concentrations of RBP4, omentin-1, visfatin, vaspin, serum uric acid, high-sensitivity C-reactive protein (hsCRP), HOMA-IR, anthropometric parameters were studied at the enrollment and 12 weeks later on the background of liraglutide therapy.Results. In gout patients with obesity, an increase in RBP4 and visfatin levels was revealed with a simultaneous decrease in omentin-1 and vaspin compared with patients in the control group and patients with gout with no metabolic disorders. The interrelationships of RBP4 and omentin-1 with the following metabolic syndrome components were established: BMI, increased triglycerides (TGs), increased total cholesterol, hsCRP, HOMA-IR and hyperinsulinemia, and reduced vaspin levels showed only a positive relationship with the HDL-C concentration (p<0,05). Visfatin positively correlates with diastolic blood pressure (r=0,29, p<0,01), the number of involved joints (r=0,577, p<0,01), the number of gout attacks (r=0,63, p<0,001).Conclusion. RBP4 and omentin-1 correlate with BMI and increased insulin sensitivity, whereas visfatin demonstrates an association with hyperuricemia and severity of gouty arthritis. Liraglutide therapy contributes to weight loss by 11,0±5,7%, improves the metabolic profile of patients with gout, increasing the content of omentin-1, lowering the RBP4 and uric acid serum concentration.

Keywords